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Systematic meta-analyses and field 
synopsis of genetic and epigenetic 
studies in paediatric inflammatory 
bowel disease
Xue Li1, Peige Song1, Maria Timofeeva2, Xiangrui Meng1, Igor Rudan1, Julian Little3, 
Jack Satsangi4, Harry Campbell1 & Evropi Theodoratou1
We provide a comprehensive field synopsis of genetic and epigenetic associations for paediatric 
Inflammatory Bowel Disease (IBD). A systematic review was performed and included 84 genetic 
association studies reporting data for 183 polymorphisms in 71 genes. Meta-analyses were conducted  
for 20 SNPs in 10 genes of paediatric Crohn’s disease (CD) and for 8 SNPs in 5 genes of paediatric 
ulcerative colitis (UC). Five epigenetic studies were also included, but formal meta-analysis was not 
possible. Venice criteria and Bayesian false discovery probability test were applied to assess the 
credibility of associations. Nine SNPs in 4 genes were considered to have highly credible associations 
with paediatric CD, of which four variants (rs2066847, rs12521868, rs26313667, rs1800629) were 
not previously identified in paediatric GWAS. Differential DNA methylation in NOD2 and TNF-α, 
dysregulated expression in let-7 and miR-124 were associated with paediatric IBD, but not as yet 
replicated. Highly credible SNPs associated with paediatric IBD have also been implicated in adult IBD, 
with similar magnitudes of associations. Early onset and distinct phenotypic features of paediatric 
IBD might be due to distinct epigenetic changes, but these findings need to be replicated. Further 
progress identifying genetic and epigenetic susceptibility of paediatric IBD will require international 
collaboration, population diversity and harmonization of protocols.
Crohn’s disease (CD) and ulcerative colitis (UC), known as inflammatory bowel diseases (IBD), are chronic 
inflammatory gastrointestinal disorders that most commonly arise in adolescents and young adults1. In Europe 
and North America, the estimated prevalence of CD is 50–200/100,000 and of UC 120–200/100,0002. An increas-
ing incidence of IBD has been observed in both developed and developing countries2. Up to 25% of IBD incident 
cases occur in childhood and result in retarded growth, impaired skeletal development, and lack of weight gain 
or even abnormal weight loss3.
The increasing incidence and prevalence with decreased quality of life in child IBD patients has spurred ongo-
ing search for risk factors of paediatric IBD. Familial, twin and phenotypic concordance studies suggest that IBD 
is highly heritable4–6. A large number of candidate gene studies have been performed to investigate the complex 
genetic architecture underlying paediatric IBD risk. However, due to the difficulty of recruiting affected children 
because of the relatively low prevalence, most of the paediatric genetic association studies reported to date had 
relatively small sample sizes or have included predominantly young-adult subjects, which may severely limit their 
power to distinguish genetic susceptibility patterns in paediatric IBD that are distinct from that of adult-onset 
disease. To date, genome wide association studies (GWAS) of IBD have identified a total of 163 loci, including 140 
loci associated with CD and 133 associated with UC7. To detect susceptibility genes related to early disease onset, 
two large GWAS have been reported with cases diagnosed before the age of 19 years, and identified 7 novel loci 
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which were thought to be exclusive to early-onset IBD8,9. However, further meta-analysis of adult GWAS showed 
that these 7 loci were also implicated in adult-onset disease7.
Although genetic studies have identified a large number of IBD risk loci, the majority of the identified variants 
are located in noncoding regions and explain a small proportion of the variance in disease risk (13.6% for CD and 
7.5% for UC)7. Epigenetic changes may mediate interactions between genes and environmental factors such as the 
gut microbiome, smoking and infection, and thus might explain some of the missing heritability10. For paediatric 
IBD specifically, epigenetic changes through exposures in utero, perinatal and early-life stage to environmental 
agents may at least partly explain the early disease onset11.
We report a comprehensive review of genetic and epigenetic studies in paediatric IBD, using the guidelines 
established by Human Genome Epidemiology Network (HuGENet)12. We reviewed all candidate-gene associ-
ation studies and performed meta-analyses for variants with genotype data available in at least three studies. A 
well-defined framework was employed to assess the credibility of the associations and thus to identify the genetic 
variants with robust evidence of association with paediatric IBD. In addition, we systematically reviewed and 
summarised reported epigenetic associations with paediatric IBD; a formal meta-analysis could not be performed 
because of differences between studies in types of tissue investigated and assays used.
Methods
Literature search and selection criteria. We searched three databases (Medline, EMBASE and the 
HuGENet web resource) (Supplementary Table S1). Studies were screened for eligibility independently by two 
authors (XL and PS) based on a pre-defined set of inclusion and exclusion criteria. Case–control and cohort stud-
ies of associations between paediatric IBD and SNPs, DNA methylation or miRNA expression were potentially 
eligible for inclusion. Paediatric IBD cases were defined as patients diagnosed in childhood or adolescence (i.e. 
before the age of 18 years). Articles that did not specify the age structure of their study populations, family-based 
studies, and studies that only investigated disease progression, pathological or histological phenotype were 
excluded. Studies that did not provide sufficient information about genotype or allele distribution of variants, and 
studies published in abstract form only, were excluded.
Data extraction and management. For each study, the following data were extracted by two authors 
(XL and PS) independently: (1) identification details: the authors, publication year, study location, study design, 
sample size, age cut-off of paediatric IBD, diagnosis criteria, and sample source; (2) participant characteristics: age 
of disease onset, age structure of study population, and ethnicity; (3) genetic information: genes, polymorphisms, 
reference allele, allele frequency, allelic and genotypic counts; (4) epigenetic changes: loci with differential DNA 
methylation and miRNAs with dysregulated expression. Double extracted data were checked by a third author 
(XM) and any discrepancies were resolved by discussion.
Statistical analysis for genetic association studies. Statistical analysis was conducted using the R soft-
ware (R x64 3.0.1). Meta-analyses were performed only for the variants with data available from at least three 
independent studies. Summary crude odds ratios (ORs) and 95% confidence intervals (95% CI) for four genetic 
models were calculated by using either the fixed-effect or random-effect model13. When there was no significant 
heterogeneity, the fixed-effect model was applied; otherwise the random-effect model. The Q statistic (with a 
threshold of p-value < 0.05) and I2 metric were calculated to quantify heterogeneity. Funnel plot analysis with an 
Egger test was conducted to test for small study effect. Statistical power was estimated by the Power and Sample 
Size Program. Hardy–Weinberg equilibrium (HWE) in controls was analysed by chi-square or Fisher’s exact test 
for each individual study. Sensitivity analysis was performed by excluding studies violating HWE or studies about 
non-white populations. Linkage disequilibrium (LD) between SNPs in the same genes was checked using the 
databases of 1000 Genomes (http://www.1000genomes.org/).
Credibility of genetic association. We applied the Venice criteria12 and Bayesian false-discovery proba-
bility (BFDP)14 to assess the credibility of the observed associations.
With Venice criteria, the credibility of associations was assessed for three criteria: the amount of evidence, 
the extent of replication and protection from bias12. We used statistical power to assess the volume of evidence; a 
grade of A, B, and C was assigned respectively when statistical power was greater than 80%, 50–79%, or less than 
50%. The extent of replication was assessed by the measurement of heterogeneity (I2 value): A, 25% or less; B, 
25–49%; C, 50% or more. For protection from bias, complete assessment is difficult. We assigned “B” to associa-
tions for which no small study effect was detected; otherwise, “C” was assigned.
BFDP was estimated to assess the noteworthiness of observed associations by using the Excel Calculation 
Spreadsheet (http://faculty.washington.edu/jonno/cv.html) on a prior level of 0.0514. A noteworthy threshold was 
defined as 0.2 based on the assumption that the cost of false discovery would be four times higher than a false 
non-discovery.
Genetic associations were classified into three categories based on the above assessment. Associations were 
classified as “highly credible” when (1) the association was statistically significant (p-value < 0.05) in at least two 
genetic models; (2) the BFDP value was less than 0.20 ; (3) the statistical power was greater than 80%; and (4) 
I2 was less than 50%. “Less credible” associations were defined as associations that were statistically significant 
(p-value < 0.05) in at least one genetic model, with BFDP value greater than 0.20, and statistical power between 
50% and 79%. All other associations were considered to be “not credible”.
Results
Genetic association studies. Study characteristics. A total of 3,137 citations were identified. After title 
and abstract review, 1,208 publications were reviewed in full text; 84 publications were finally included, 79 
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of which were on paediatric CD, 34 on paediatric UC and 5 on paediatric IBD (Fig. 1). Characteristics of the 
included studies are presented in Supplementary Table S2. Of these, the majority of the studies (n = 57, 67.9%) 
were conducted in pediatric or early-onset IBD patients younger than 17 years, while 10 studies (11.9%) focused 
on IBD patients below 16 years and 17 studies (20.2%) focused on IBD patients below 18 years. The geographic 
distribution of the study populations (Supplementary Fig. S1) suggests a lack of population diversity in exploring 
the genetic factors of paediatric IBD, since more than 90% of the studies (n = 78) were conducted among white 
populations and only a small number of studies were conducted in Asian (n = 6, 7.6%) and African American 
(n = 1, 1.3%).
One hundred and eighty three polymorphisms in 71 genes were identified (147 polymorphisms in 58 genes in 
paediatric CD, 80 polymorphisms in 40 genes in paediatric UC, and 29 polymorphisms in 8 genes in paediatric 
IBD). Thirty five variants were found to be positively associated with paediatric CD in genetic association studies 
and twenty of them (57.1%) were confirmed in GWAS. Fifteen variants were identified to have positive associa-
tions with paediatric UC and ten of them (66.7%) were confirmed in GWAS (Supplementary Table S3).
Meta-analyses results. Meta-analyses were conducted for 20 variants in paediatric CD and 8 variants in paedi-
atric UC, for which data were available in three or more independent studies (Table 1). Meta-analyses of paedi-
atric CD included 7 (mean; range: 3–16) independent studies with 854 (mean; range: 165–2059) cases and 2137 
(mean; range: 369–6385) controls. Meta-analyses of paediatric UC included 4 (mean; range: 3–6) independent 
studies with 385 (mean; range: 318–606) cases and 1039 (mean; range: 800–1515) controls. For two variants 
(rs2066844, rs2241880) in paediatric CD and 1 variant (rs2066844) in paediatric UC, some of the studies violated 
HWE (p < 0.05). For two variants (rs2066844, rs2066847) in paediatric CD, one studies was conducted in African 
Americans. Four pairs of SNPs were found in LD with r2 threshold ≥ 0.60 (Supplementary Table S4).
Paediatric CD. Meta-analyses of 20 variants in four genetic models for paediatric CD are presented in Tables 2 and 3. 
Eleven variants had summary ORs with p-value < 0.05 in at least two genetic models. Associations with 9 var-
iants (rs2066844, rs2066845, rs2066847, rs11209026, rs7517847, rs12521868, rs26313667, rs2241880 and 
rs1800629) were considered as the most highly-credible, due to the high statistical power (> 0.80), small het-
erogeneity (I2 < 50%) and low BFDP (< 0.20); the other 2 variants (rs11739135, rs1050152) were considered as 
less-credible SNPs. ORs and 95% CI of individual studies for each variant and each model are shown in forest 
plots in Supplementary Fig. S2–S21. Funnel plots with Egger tests are shown in Supplementary Fig. S22–S41.
Among the highly credible variants, rs2066844, rs2066845, rs11209026, rs7517847 and rs2241880 achieve 
genome-wide significance in both paediatric and adult-onset IBD GWAS (Table 4). Rs2066847 and rs12521868 
were found to be genome-wide significant only in adult-onset IBD GWAS. Rs26313667 and rs1800629 have not 
been previously identified in either paediatric or adult-onset IBD GWAS.
Paediatric UC. Tables 5 and 6 present the results of meta-analyses of 8 variants for paediatric UC. Four variants 
(rs2066844, rs2066847, rs11209026, rs1800629) had significant associations with p-values < 0.05 in at least two 
genetic models, but none of them were classified as highly-credible associations either because of the high BFDP 
(> 0.20) or low statistical power (< 0.80). ORs and 95% confidence intervals of individual studies for each variant 
and each model are shown in forest plots in Supplementary Fig. S42–S49. Funnel plots with Egger tests are shown 
in Supplementary Fig. S50–S57.
Sensitivity Analysis. Sensitivity analysis was conducted in three variants (rs2066844, rs2066847, rs2241880) for 
paediatric CD and one variant (rs2066844) for paediatric UC by excluding a study of non-white population and 
a study with variants violating HWE (Supplementary Tables S5–S8). Sensitivity analyses did not reveal major dif-
ferences in genetic effects. Rs2066844, rs2066847 and rs2241880 remained statistically significant (p < 0.05) with 
small changes in summary ORs and credibility assessment showed no inconsistencies with the previous analysis.
Figure 1. Flow charts for the selection of eligible genetic and epigenetic studies. 
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Epigenetic studies. After screening 408 titles and abstracts, 62 papers were reviewed in full text. Five studies met the 
inclusion and exclusion criteria, with three of them focusing on changes in DNA methylation and two investigating 
miRNA expression changes (Fig. 1, Supplementary Table S9, Table 7). Genome-wide DNA methylation analysis in 
peripheral blood leukocyte was performed in two studies using the same methylation platform; there was no overlap 
in differential methylated genes. A DNA methylation study in intestinal biopsies highlighted 6 genes which were 
associated with colonic mucosal immune and defence responses. In addition, dysregulated expression in 26 miRNAs 
was observed in paediatric IBD cases, two of which (miR-124 and let-7) were reported in both paediatric studies.
Gene/
Variant
Cases/
controls
No. of 
studies
Ref 
allele
Ref allele 
frequency cases
Ref allelefrequency 
controls
MAF (1000 
Genomes)
Result of most recent meta-
analysis in adult-onset IBD; 
cases/controls (studies); 
(reference)
Result of meta-analysis 
in paediatric IBD; 
cases/controls (studies); 
(reference)
Paediatric CD
NOD2
rs2066844 1984/4179 16 C 0.912 0.958 0.014 Pos assoc; 17666/15491(72)44 n/a
rs2066845 2059/4280 16 G 0.941 0.976 0.005 Pos assoc; 17651/15908(72)44 n/a
rs2066847 1980/4234 16 G 0.872 0.976 0.006 Pos assoc; 18727/17102(79)44 n/a
rs5743289† 376/507 3 C n/a n/a 0.052 n/a n/a
IL23R
rs11209026 1158/4766 10 G 0.977 0.923 0.023 Pos assoc; 8110/11900(33)22 Pos assoc; 818/1958(5)22
rs7517847 496/1383 4 T 0.654 0.588 0.356 Pos assoc; 3279/4136(11)15 n/a
IBD5
rs11739135 536/722 4 G 0.548 0.592 0.135 Pos assoc; 2295/2348(9)16 n/a
rs12521868 536/742 4 G 0.525 0.596 0.138 Pos assoc; 2788/3085(10)16 n/a
rs17622208 527/872 3 G 0.673 0.681 0.190 Pos assoc; 1686/1975(7)16 n/a
rs1050152 757/1474 7 C 0.528 0.577 0.134 Pos assoc; 4489/5351(15)17 Pos assoc; 485/922(5)16
rs26313667 653/1117 5 G 0.462 0.523 0.267 Pos assoc; 4474/5377(15)17 Pos assoc; 472/910(5)16
ATG16L1
rs2241880 1360/6385 12 G 0.594 0.543 0.396 Pos assoc; 12762/16735(35)22 Pos assoc;1135/2457(6)22
DLG5
rs1248696 427/846 4 C 0.919 0.898 0.034 No assoc; n/a (12)45 n/a
rs2289311 165/750 3 G 0.700 0.646 0.262 n/a n/a
PSMG1
rs2836878 425/705 3 G 0.746 0.748 0.209 n/a n/a
TNF-α
rs1800629 509/1443 6 G 0.830 0.882 0.090 No assoc; 3201/5033(20)46 n/a
rs1799724 326/854 3 C 0.842 0.870 0.099 No assoc; 2291/3796(11)46 n/a
PTPN2
rs2542151 461/2152 4 T 0.858 0.862 0.174 Pos assoc; 9804/10642(13)47 n/a
TLR4
rs4986790† 214/369 3 A n/a n/a 0.060 Pos assoc; n/a (33)48 n/a
BSN-MST1
rs9858542† 414/679 3 G n/a n/a 0.195 n/a n/a
Paediatric UC
NOD2
rs2066844 606/1512 6 C 0.94 0.96 0.014 No assoc; 6240/7350(32)44 n/a
rs2066845 591/1515 6 G 0.98 0.98 0.005 No assoc; 6016/6840(29)44 n/a
rs2066847 576/1240 6 G 0.97 0.98 0.006 No assoc; 6403/7875(35)44 n/a
IL23R n/a
rs11209026 358/1344 3 G 0.96 0.94 0.023 Pos assoc; 5438/7380(16)49 n/a
IBD5
rs1050152 392/1056 4 C 0.53 0.57 0.134 Pos assoc; 2923/4660(12)16 No assoc; 279/800(3)16
rs26313667 392/1044 4 G 0.48 0.52 0.267 Pos assoc; 2911/4635(12)16 No assoc; 279/788(3)16
DLG5
rs1248696 318/800 3 C 0.92 0.90 0.034 n/a n/a
TNF-α
rs1800629 235/844 3 G 0.87 0.88 0.090 No assoc; 2423/4367(14)50 n/a
Table 1.  List of genes and variants selected for meta-analyses of paediatric CD and UC (sorted by gene). 
†For variants with genotype data reported as risk allele carrier (wt/var & var/var vs. wt/wt), reference allele 
frequency is unable to be calculated and meta-analyses were performed only in dominant model.
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Discussion
This study offers a comprehensive and up-to-date assessment of genetic and epigenetic literature in paediatric 
IBD. We systematically evaluated data from 84 studies for 183 variants in 71 candidate genes. It differs from other 
meta-analyses of genetic effect on IBD15–17, since it integrates information of all variants that were investigated 
in genetic association studies of paediatric IBD. We only included studies conducted in children younger than 
18 years old and not studies considering patients 19–21 years old or adults. This study is the first field synopsis 
of paediatric IBD with the advantage of evaluating both genetics and epigenetic associations. A well-defined 
assessing framework, including the Venice criteria and BFDP, were used to classify the identified associations. 
After credibility assessment, this study indicated three variants (rs2066844, rs2066845, rs2066847) in NOD2, 
two variants (rs11209026, rs7517847) in IL23R, one variant (rs2241880) in ATG16L1, two variants (rs12521868, 
rs26313667) in the IBD5 region and one variant (rs1800629) in TNF-α represented the most credible findings 
and were referred as highly-credibly associated with paediatric IBD. Four (rs2066847 in NOD2, rs12521868 and 
rs26313667 in IBD5, rs1800629 in TNF-α) of these variants have not been identified in the GWAS of paediatric 
IBD. In addition, all of the identified variants have been found also to be associated with adult IBD either by can-
didate gene studies or GWAS.
The contribution of NOD2 gene to CD risk has been confirmed in multiple GWAS of European ancestry 
adults7. Our study further supported the evidence that three SNPs (rs2066844, rs2066845, rs2066847) in NOD2 
were each highly associated with increased paediatric CD risk. Compared with a meta-analysis of adult-onset CD, 
the effect sizes of these three SNPs in children were similar to those in adults18. The summary ORs of rs2066844, 
rs2066845 and rs2066847 variants estimated for paediatric CD in this study were 2.23 (95% CI: 1.88–2.64), 3.21 
(95% CI: 2.25–4.6) and 5.78 (95% CI: 3.67–9.11) respectively. The equivalent summary ORs for adult onset 
CD associated with these variants were 2.20 (95% CI: 1.84–2.62), 2.99 (95% CI: 2.38–3.74) and 4.09 (95% CI: 
3.23–5.18) respectively18, suggesting no stronger genetic associations in children. In contrast, the association 
between the NOD2 gene and UC remains somewhat controversial. Most of the available data suggest no associ-
ation between NOD2 mutations and UC susceptibility. The findings of this study indicated that the frequency of 
rs2066844 and rs2066847 variants was significantly higher in paediatric UC patients than in healthy children sug-
gesting a possible involvement of NOD2 in paediatric UC. However, due to the limited statistical power and high 
probability of false discovery, this association between the NOD2 gene variant and paediatric UC susceptibility is 
considered as “less credible” and needs further study and elucidation.
The association of IL23R with adult IBD risk was established in a GWAS19, and then was confirmed in genome 
wide meta-analysis7. A paediatric GWAS conducted by Imielinski et al. replicated this association in children8. 
Consistent with these findings, our study confirmed the IL23R association in both paediatric CD and UC. It was 
estimated that the rs11209026 variant conferred approximately a 3-fold reduction in the risk of paediatric CD. 
For paediatric UC, the protective effect was significant but less-credible (OR = 0.54; 95% CI: 0.35–0.84) due to the 
high probability of false discovery. In addition, homozygosity for the rs7517847 variant was also credibly associ-
ated with paediatric CD (OR = 0.47, 95% CI: 0.32–0.67). A recent meta-analysis of rs7517847 estimated an odds 
ratio of 0.49 (95% CI: 0.38–0.64) for adult-onset CD risk15, suggesting no substantial difference in genetic effect 
size between paediatric and adult-onset CD.
IBD5 region encompasses several candidate genes which were initially suggested to be associated with 
early-onset IBD20. The study showed IBD5 region had strong association with early-onset CD, but only exerted 
a moderate effect on adult-onset CD. Subsequently, Mirza et al. reported a correlation between genes in IBD5 
region and age of CD onset21. In the present study, we confirmed the significant associations of two variants 
(rs26313667 and rs12521868) in the IBD5 region with paediatric CD, but no stronger effects than those observed 
in adult population. Variant homozygotes of rs26313667 had an estimated OR of 1.68 (95% CI: 1.26–2.23), which 
was not significantly greater than that in adult-onset CD (OR = 1.39; 95% CI: 1.15–1.67)16. Our finding was 
in concordance with the study of Wang J et al., which reported an effect size of 1.68 (95% CI: 1.21–2.33) for 
children16. In addition, a highly credible association was observed with homozygosity for rs12521868, with a 
summary OR of 1.88 (95% CI: 1.34–2.62), similar to the reported magnitude of association for adults (OR = 1.83; 
95% CI: 1.54–2.71)16. Therefore, we conclude that variants within the IBD5 region increase CD susceptibility with 
no distinct specification to paediatric CD. Of particular note, identification of the precise causal gene in IBD5 
region has proved to be challenging, due to the extensive degree of linkage disequilibrium between the examined 
polymorphisms.
In the ATG16L1 gene, the rs2241880 polymorphism was identified to be associated with paediatric CD. 
Association of rs2241880 with adult-onset CD has been confirmed in multiple GWAS7. Association of this vari-
ant with paediatric CD were also established in two GWAS conducted among children8,9. Our study further rein-
forced this association with paediatric CD based on evidence from candidate gene studies. A recent meta-analysis 
reported an OR of 0.71 (95% CI: 0.53-0.95) in paediatric CD homozygotes22. This finding was similar to our study 
(OR = 0.61, 95%CI: 0.51–0.74). It is noteworthy that the common variant of rs2241880 confers an increase in 
disease risk (frequency of risk allele G = 0.63). ATG16L1 is involved in autophagy and plays an important role 
in the degradation of intracellular pathogens and antigen processing23. Therefore, a possible explanation for the 
increased risk may be that while this common variant functions as a protective factor against infection, it may 
increase the risk of inflammatory disorders or autoimmunity.
DLG5 is the gene coding for an important scaffolding protein in maintaining epithelial structure and colonic 
barrier function. Since the original report identified DLG5 as a candidate gene for IBD risk24, this association 
has been replicated in some studies but not all. Well powered studies in various populations failed to find any 
disease association25,26. In the genome wide meta-analysis of IBD patients, DLG5 did not achieve genome-wide 
significance7. Our study found that DLG5 variant (rs1248696) was not correlated with paediatric IBD. Despite 
the inability to replicate this association, we cannot rule out the possibility that DLG5 plays a role in IBD patho-
genesis in specific populations. The varied association of DLG5 gene may be explained by genetic heterogeneity 
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and a moderate effect. It is important to emphasize that, as a weak factor, a disease-causative effect could be easily 
modified in either a positive or negative way by gene-environment interactions. Therefore, even in the same pop-
ulation with the application of identical diagnostic criteria, variation in environmental exposures could lead to 
differences in genetic association.
The polymorphic rs2836878 variant is located on chromosome 21q22, a region of linkage disequilibrium that 
harbours no genes but is close to the PSMG1 gene. This variant was identified as linked to early onset IBD in both 
paediatric IBD GWAS8,9. These observations interpreted as indicating that PSMG1 is a paediatric-specific IBD 
related gene. However, association with PSMG1 was later detected in a large scale meta-analysis of adult-onset 
GWAS7. Although the association of PSMG1 gene was confirmed in both paediatric and adult-onset GWAS, the 
candidate gene studies presented inconsistent results. Four candidate gene studies were conducted to verify the 
role of PSMG1 gene in paediatric IBD27–30. First, a Canadian study, which was excluded from the present analysis 
because it did not meet the age cut-off of paediatric IBD, observed a suggestion of association with the rs2836878 
Gene/ Variant
Cases vs. 
controls 
(number of 
samples)
DOMINANT MODEL: wt/var & var/var VS. wt/wt RECESSIVE MODEL: var/var vs. wt/wt & wt/var
N Effect size Heterogeneity Credibility N Effect size Heterogeneity Credibility
OR  
(95% CI) P value
I^2  
(95% CI) Power BFDP1
Venice 
criteria 
grade OR (95% CI) P value
I^2 
(95% CI) Power BFDP1
Venice 
criteria 
grade
NOD2/rs2066844 1984 vs. 4179 (16) 16
2.23  
(1.88, 2.64) 4.77E-20
46  
(2, 82) 1.00 0.000 ABB 12
4.14  
(2.18, 7.89) 1.54E-05 0 (0, 49) 0.99 0.035 AAB
NOD2/rs2066845 2059 vs. 4274 (16) 16
3.21  
(2.25, 4.60) 1.61E-10
53  
(10, 84) 1.00 0.000 ACB 11
8.64  
(2.80, 26.69) 1.77E-04 0 (0, 0) 1.00 0.465 AAB
NOD2/rs2066847 1980 vs. 4234 (16) 16
5.78  
(3.67, 9.11) 4.12E-14
77  
(58, 92) 1.00 0.000 ACB 10
91.00  
(25.07, 330.27) 6.97E-12 0 (0, 57) 1.00 0.000 AAB
NOD2/rs5743289 376 vs. 687 (3) 3
1.48  
(1.13, 1.94) 0.004 0 (0, 0) 0.83 0.640 AAB n/a n/a n/a n/a n/a n/a n/a
IL23R/ rs11209026 1158 vs. 4766 (10) 10
0.32  
(0.23, 0.43) 2.10E-13 0 (0, 50) 1.00 0.000 AAB 7
0.97  
(0.31, 3.04) 0.952 0 (0, 32) 0.05 0.963 CAB
IL23R/rs7517847 496 vs. 1383 (4) 4
0.66  
(0.53, 0.83) 3.13E-04 0 (0, 79) 0.95 0.180 AAB 4
0.57  
(0.41, 0.79) 8.97E-04 49 (0, 94) 0.96 0.262 ABB
IBD5/rs11739135 536 vs. 722 (4) 4
1.24  
(0.97, 1.59) 0.082 48 (0, 98) 0.41 0.956 CBB 4
1.41  
(1.05, 1.89) 0.024 28 (0, 98) 0.63 0.862 BBB
IBD5/rs12521868 536 vs. 731 (4) 4
1.35  
(1.05, 1.73) 0.018 0 (0, 95) 0.68 0.856 BAB 4
1.76  
(1.31, 2.35) 1.55E-04 0 (0, 23) 0.97 0.072 AAB
IBD5/rs17622208 527 vs. 872 (3) 3
1.38  
(1.05, 1.81) 0.020 51 (0, 92) 0.83 0.861 ACB 2
1.28  
(0.92, 1.78) 0.140 0 (0, 0) 0.33 0.961 CAB
IBD5/rs1050152 757 vs. 1534 (7) 7
1.20  
(0.98, 1.47) 0.072 0 (0, 76) 0.45 0.959 CAB 7
1.48  
(1.17, 1.86) 9.91E-04 0 (0, 79) 0.93 0.293 AAB
IBD5/rs26313667 653 vs. 1117 (5) 5
1.40  
(1.11, 1.77) 0.005 0 (0, 83) 0.82 0.675 AAB 5
1.42  
(1.13, 1.78) 0.003 0 (0, 7) 0.87 0.527 AAB
ATG16L1/rs2241880 1360 vs. 6385 (12) 12
0.70  
(0.62, 0.81) 3.14E-07 0 (0, 53) 1.00 0.002 AAB 12
0.73  
(0.62, 0.87) 2.70E-04 0 (0, 51) 0.90 0.225 ACB
DLG5/rs1248696 427 vs. 846 (4) 4
0.79  
(0.57, 1.09) 0.148 0 (0, 94) 0.34 0.961 CAB 4
0.56  
(0.14, 2.26) 0.416 0 (0, 81) 0.12 0.955 CAB
DLG5/rs2289311 165 vs. 750 (3) 3
0.76  
(0.53, 1.10) 0.151 19 (0, 98) 0.36 0.958 CAB 3
0.55  
(0.29, 1.06) 0.075 0 (0, 97) 0.50 0.920 BAB
PSMG1/rs2836878 425 vs. 705 (3) 3
1.06  
(0.83, 1.36) 0.623 43 (0, 98) 0.07 0.987 CBB 3
0.98  
(0.33, 2.91) 0.971 67 (0, 99) 0.05 0.964 CCB
TNF-α/rs1800629 509 vs. 1443 (5) 5
1.98  
(1.29, 3.03) 0.002 57 (0, 96) 1.00 0.415 ACB 4
3.79  
(1.96, 7.32) 7.52E-05 0 (0, 95) 0.98 0.101 AAB
TNF-α/rs1799724 326 vs. 854 (3) 3
0.90  
(0.67, 1.22) 0.501 47 (0, 99) 0.10 0.983 CBB 3
0.63  
(0.28, 1.41) 0.259 0 (0, 95) 0.13 0.955 CAB
PTPN2/rs2542151 461 vs. 2152 (3) 3
1.05  
(0.83, 1.33) 0.667 0 (0, 82) 0.07 0.988 CAB 3
1.77  
(0.88, 3.55) 0.108 0 (0, 95) 0.42 0.934 CAB
TLR4/rs4986790 214 vs. 369 (3) 3
1.54  
(0.92, 2.58) 0.100 20 (0, 97) 0.38 0.937 CAB n/a n/a n/a n/a n/a n/a n/a
BSN-MST1/rs9858542 414 vs. 679 (3) 3
2.08  
(1.62, 2.68) 1.00E-05 13 (0, 83) 1.00 0.030 AAB n/a n/a n/a n/a n/a n/a n/a
Table 2.  Summary crude odds ratios (ORs) and 95% confidence intervals (95% CI) for dominant and 
recessive models for variants that were identified for meta-analysis with credibility factors in paediatric 
CD. Venice criteria grade for the three criteria. The first grade is for the amount of evidence assessed according 
to statistical power (A, ≥ 80%; B, 50–79%; C, < 50%); the second grade is for the extent of replication assessed 
according to heterogeneity (I2 value: A, < 25%; B, 25–50%; C, > 50%); the third grade is for protection from 
bias assessed according to small study effect (complete assessment of bias is difficult; no variants were graded 
as “A”; “B” was assigned for studies which no small study effect was detected; otherwise, “C” was assigned). 
Bayesian False Discovery Probability (BFDP) value were calculated at prior probability of 0.05. BFDP level of 
noteworthiness is 0.2.
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variant but this was not statistically significant27. Among the other three studies, two reported significant asso-
ciations29,30, but the third, a larger study found no association28. After synthesizing data from these 3 studies, the 
association between rs2836878 and paediatric IBD was not statistically significant. Considering that small sample 
size and large genetic heterogeneity among populations may be responsible for the observed discrepancy, a larger 
study including functional data on PSMG1 is required to elucidate the role of this gene in the pathogenesis of IBD.
The TNF-α gene has been identified as an IBD-susceptibility locus in genome wide scans7. Rs1800629 and 
rs1799724, two polymorphic variants of the TNF-α gene, have been studied extensively. Conflicting findings were 
observed in the associations between these polymorphisms and IBD development. A meta-analysis of genetic 
association studies of rs1800629 polymorphism in adulthood CD suggested no association31. Further pheno-
typic analysis reported that the rs1800629 polymorphism was more frequent in patients with steroid-dependent, 
colonic involvement and fistulising behaviour32. Our study extended consideration of the possible role of 
rs1800629 in paediatric CD by synthesizing data from five independent studies, and found a highly-credible 
association. This finding was consistent with the result of phenotype analysis reporting that colonic involvement 
and fistulising behaviour are more common in paediatric CD. For rs1799724, an association with adult CD has 
been reported and replicated in several studies, but no association was observed in paediatric patients33.
An association between the PTPN2 gene and IBD has been confirmed in GWAS among adults34. Our study 
synthesized data on the rs2542151 polymorphism in PTPN2 gene and paediatric IBD, and found no association, 
which is consistent with the findings of paediatric GWAS8,9. The explanation for the difference effect of rs2542151 
Gene/ Variant
Cases vs. 
controls 
(number of 
samples)
ADDITIVE MODEL 1: var/wt VS. wt/wt ADDITIVE MODEL 2: var/var VS. wt/wt
N Effect size Heterogeneity Credibility N Effect size Heterogeneity Credibility
OR (95% 
CI) P value
I^2 
(95% CI) Power BFDP1
Venice 
criteria 
grade OR (95% CI) P value
I^2 
(95% CI) Power BFDP1
Venice 
criteria 
grade
NOD2/rs2066844 1984 vs. 4179 (16) 16
2.11  
(1.77, 2.52) 9.81E-17 36 (0, 78) 1.00 0.000 ABB 12
4.44  
(2.34, 8.43) 5.26E-06 0 (0, 54) 0.99 0.016 AAB
NOD2/rs2066845 2059 vs. 4274 (16) 16
3.02  
(2.42, 3.76) 5.04E-23 50 (6, 82) 1.00 0.000 ABB 11
9.18  
(2.99, 28.22) 1.09E-04 0 (0, 0) 1.00 0.405 AAB
NOD2/rs2066847 1980 vs. 4234 (16) 16
5.03 (3.34, 
7.59) 1.34E-14
70 (46, 
89) 1.00 0.000 ACB 10
105.94 (30.65, 
366.14) 1.72E-13 0 (0, 67) 1.00 0.000 AAB
IL23R/ rs11209026 1158 vs. 4766 (10) 10
0.33  
(0.24, 0.44) 8.29E-13 0 (0, 51) 1.00 0.000 AAB 7
0.88  
(0.29, 2.76) 0.823 0 (0, 30) 0.06 0.963 CAB
IL23R/rs7517847 496 vs. 1383 (4) 4
0.73  
(0.58, 0.93) 0.010 0 (0, 41) 0.80 0.800 AAB 4
0.47  
(0.32, 0.67) 4.11E-05 45 (0, 93) 1.00 0.023 ABB
IBD5/rs11739135 536 vs. 722 (4) 4
1.17  
(0.90, 1.51) 0.245 15 (0, 97) 0.23 0.977 CAB 4
1.55  
(1.11, 2.17) 0.011 56 (0, 99) 0.73 0.767 BCB
IBD5/rs12521868 536 vs. 731 (4) 4
1.20  
(0.92, 1.55) 0.178 0 (0, 94) 0.28 0.971 CAB 4
1.88  
(1.34, 2.62) 2.22E-04 0 (0, 96) 0.96 0.101 AAB
IBD5/rs17622208 527 vs. 872 (3) 3
1.33  
(1.00, 1.78) 0.050 53 (0, 92) 0.54 0.930 BCB 2
1.61  
(1.09, 2.37) 0.020 34 (0, 85) 0.64 0.811 BBB
IBD5/rs1050152 757 vs. 1534 (7) 7
1.09  
(0.88, 1.35) 0.416 0 (0, 76) 0.13 0.987 CAB 7
1.55  
(1.18, 2.02) 0.001 0 (0, 79) 0.92 0.360 AAB
IBD5/rs26313667 653 vs. 1117 (5) 5
1.28  
(1.00, 1.64) 0.051 0 (0, 84) 0.51 0.934 BAB 5
1.68  
(1.26, 2.23) 3.67E-04 0 (0, 67) 0.96 0.153 AAB
ATG16L1/rs2241880 1360 vs. 6385 (12) 12
0.74  
(0.64, 0.86) 4.14E-05 0 (0, 33) 0.98 0.067 AAB 12
0.61  
(0.51, 0.74) 2.85E-07 4 (0, 60) 1.00 0.001 AAB
DLG5/rs1248696 427 vs. 846 (4) 4
0.80  
(0.57, 1.12) 0.192 0 (0, 93) 0.27 0.968 CAB 4
0.55  
(0.14, 2.21) 0.397 0 (0, 82) 0.13 0.955 CAB
DLG5/rs2289311 165 vs. 750 (3) 3
0.84  
(0.57, 1.23) 0.371 4 (0, 98) 0.16 0.976 CAB 3
0.51  
(0.26, 1.01) 0.053 0 (0, 97) 0.58 0.954 BAB
PSMG1/rs2836878 425 vs. 705 (3) 3
1.13  
(0.88, 1.46) 0.339 0 (0, 96) 0.16 0.982 CAB 3
1.10  
(0.33, 3.72) 0.872 72 (0, 99) 0.07 0.962 CCB
TNF-α/rs1800629 509 vs. 1443 (5) 5
1.91  
(1.27, 2.85) 0.002 51 (0, 95) 1.00 0.397 ACB 4
4.75  
(2.43, 9.26) 4.86E-06 0 (0, 96) 1.00 0.017 AAB
TNF-α/rs1799724 326 vs. 854 (3) 3
0.94  
(0.69, 1.29) 0.718 47 (0, 99) 0.07 0.985 CBB 3
0.60  
(0.26, 1.36) 0.221 0 (0, 96) 0.15 0.952 CAB
PTPN2/rs2542151 461 vs. 2152 (3) 3
1.01  
(0.79, 1.28) 0.955 0 (0, 0) 0.05 0.989 CAB 3
1.77  
(0.88, 3.56) 0.108 0 (0, 95) 0.42 0.934 CAB
Table 3.  Summary crude odds ratios (ORs) and 95% confidence intervals (95% CI) for two additive models for 
variants that were identified for meta-analysis with credibility factors in paediatric CD. Venice criteria grade for 
the three criteria. The first grade is for the amount of evidence assessed according to statistical power (A, ≥ 80%;  
B, 50–79%; C, < 50%); the second grade is for the extent of replication assessed according to heterogeneity (I2 value: 
A, < 25%; B, 25–50%; C, > 50%); the third grade is for protection from bias assessed according to small study effect 
(complete assessment of bias is difficult; no variants were graded as “A”; “B” was assigned for studies which no small 
study effect was detected; otherwise, “C” was assigned). Bayesian False Discovery Probability (BFDP) value were 
calculated at prior probability of 0.05. BFDP level of noteworthiness is 0.2.
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polymorphism on adults and children is not yet clear, but phenotypic analysis indicated that the PTPN2 gene had 
a role in patients with older age-at-diagnosis or who were smokers35.
The identified epigenetic studies found differential DNA methylation in IBD susceptibility loci involved in 
the immune response36. Methylation changes in NOD2, which in the present study is classified as highly-credibly 
associated with paediatric IBD, have been reported in whole blood samples of IBD patients36. NOD2 has been 
reported to regulate the expression of miRNA-29 to reduce the release of IL-23, which indirectly influences the 
Th17 pathway in human dendritic cells37. Smoking is a known environmental modifier of epigenetic state and 
NOD2 activation38. In relation to paediatric IBD, relevant routes of exposure may include maternal active and 
passive smoking during pregnancy and/or second-hand smoking exposure in childhood. The rs1800629 variant 
of TNF-α, identified as associated with paediatric CD with high credibility, is located in a transcription factor AP2 
binding site, which is sensitive to methylation39. As the functional role of rs1800629 on TNF-α transcription is 
not clear, DNA methylation changes are perhaps important.
Two systematic reviews have been conducted to summarize observed associations between differential meth-
ylated DNA and dysregulated miRNA expression and adult IBD10,40. Comparing our results with these findings, 
differences in DNA methylation and miRNA expression patterns between child and adult IBD patients are appar-
ent. To our knowledge, among the highlighted differential methylated genes identified in paediatric IBD, only 
CFI, TNF-α and STAT3 have been replicated in adults, but not in the same tissues10,40. For the 26 dysregulated 
miRNA identified in paediatric IBD, only 8 were overlapped with those identified in adults10. In addition, par-
ticular note should be given to let-7 and miRNA-124, which have been identified in two paediatric studies41,42. 
It has been reported that both let-7 and miRNA-124 are involved in the inflammatory circuits leading to cell 
transformation through the activation of the STAT3 pathway, but miRNA-124 is specific to active paediatric UC41. 
Together with the findings of this field synopsis of genetic association studies, in which paediatric and adult-onset 
IBD share the majority of candidate genes, it is possible that epigenetic changes may be one of the reasons leading 
to the early disease onset and the distinct phenotypic features of paediatric IBD. The identified changes in DNA 
methylation and miRNA expression highlight the new aspects of disease pathogenesis and will be helpful to iden-
tify new clinical biomarkers and therapeutic targets.
In spite of the systematic internationally recognised approaches applied in this study, there is still room for 
future improvement in assessing the credibility of association. Venice criteria and BFDP improve the consistency 
and objectiveness of the interpretation and reporting of genetic associations, but this evidence does not prove 
causality. Additional evidence, such as gene knock-out experiments, gene expression microarray experiments 
or other mechanistic data are necessary to understand the specific functions of variants or genes. Associations 
with high credibility deserve in-depth evaluation including biological investigations; associations with moderate 
Highly-credible 
variants
Field synopsis of 
paediatric IBD GWAS in paediatric IBD GWAS in adult IBD
p-value OR (95%CI)
Genome-wide 
significance p-value OR (95%CI)†
Genome-wide 
significance p-value OR (95%CI)
NOD2
rs2066844 9.81E-17 2.11  (1.77, 2.52) Yes 7.44E-09
51 2.06(1.61.2.64) Yes n/a34 n/a
rs2066845 5.04E-23 3.02  (2.42, 3.76) Yes 3.00E-07
51 2.58(1.80, 3.70) Yes 4.62E-0834 n/a
rs2066847 1.34E-14 5.03  (3.34, 7.59) n/a n/a n/a Yes 2.98E-24
34; 5.86E-2097 3.99  (n/a, n/a)
IL23R
rs11209026 8.29E-13 0.33  (0.24, 0.44) Yes 3.35E-10
8 0.28(0.18, 0.43) Yes 2.15E-6834 n/a
rs7517847 0.01 0.73  (0.58, 0.93) Yes 8.22E-08
51 0.70(0.61, 0.79) Yes 3.06E-1252 n/a
IBD5
rs12521868 2.22E-04 1.88  (1.34, 2.62) No 0.002
51 1.22(1.07, 1.39) Yes 1.41E-2034 n/a
rs26313667 3.67E-04 1.68  (1.26, 2.23) n/a n/a n/a n/a n/a n/a
ATG16L1
rs2241880 4.14E-05 0.74  (0.64, 0.86) Yes 7.63E-10
8; 1.09E-189 0.69(0.61, 0.78) Yes 4.61E-2534; 4.10E-0852 0.68  (n/a, n/a)
TNF-α
rs1800629 4.86E-06 4.75  (2.43, 9.26) n/a n/a n/a n/a n/a n/a
Table 4.  Effect sizes and p-values from paediatric and adult GWAS studies of the identified highly-credible 
variants. Genome-wide significance in GWAS was checked in GWAS catalog: https://www.ebi.ac.uk/gwas/. 
P-value and OR (95%CI) reported in GWAS were estimated for minor allele code; P-value and OR (95%CI) 
reported in field synopsis were estimated for two additive models (var/wt vs. wt/wt or var/var vs. wt/wt).
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Gene/ Variant
Cases vs. 
controls 
(number of 
samples)
DOMINANT MODEL: wt/var & var/var VS. wt/wt RECESSIVE MODEL: var/var vs. wt/wt & wt/var
N Effect size Heterogeneity Credibility N Effect size Heterogeneity Credibility
OR (95% 
CI) P value
I^2 
(95% CI) Power BFDP1
Venice 
criteria 
grade
OR (95% 
CI) P value
I^2 
(95% CI) Power BFDP1
Venice 
criteria 
grade
NOD2/rs2066844 590 vs. 1512 (6) 6
1.66  
(1.20, 2.28) 0.002 34 (0, 91) 0.88 0.427 ABB 4
0.96  
(0.20, 4.68) 0.960 0 (0, 77) 0.05 0.959 CAB
NOD2/rs2066845 591 vs. 1515 (6) 6
1.14  
(0.70, 1.87) 0.600 0 (0, 87) 0.09 0.976 CAB 2
3.24  
(0.17, 63.38) 0.439 0 (0, 0) 0.30 0.951 CAB
NOD2/rs2066847 593 vs. 1502 (6) 6
1.76  
(1.11, 2.80) 0.010 0 (0, 95) 0.74 0.813 BAB n/a n/a n/a n/a n/a n/a n/a
IL23R/ rs11209026 393 vs. 1321 (3) 3
0.55  
(0.37, 0.84) 0.005 0 (0, 83) 0.85 0.653 AAB n/a n/a n/a n/a n/a n/a n/a
IBD5/rs1050152 353 vs. 1056 (4) 4
1.22  
(0.93, 1.61) 0.150 0 (0, 82) 0.31 0.968 CAB 4
1.40  
(1.03, 1.91) 0.030 0 (0, 90) 0.61 0.897 BAB
IBD5/rs26313667 353 vs. 1044 (4) 4
1.30  
(0.97, 1.75) 0.081 0 (0, 66) 0.46 0.947 CAB 4
1.29  
(0.97, 1.71) 0.085 17 (0, 98) 0.44 0.946 CAB
DLG5/rs1248696 289 vs. 800 (3) 3 0.85  (0.58, 1.24) 0.405 0 (0, 75) 0.14 0.970 CAB 3
0.74  
(0.16, 3.33) 0.690 0 (0, 97) 0.06 0.958 CAB
TNF-α /rs1800629 235 vs. 844 (3) 3 1.81  (0.82, 3.99) 0.143 69 (0, 99) 0.95 0.941 ACB 3
3.08  
(0.99, 9.55) 0.052 0 (0, 97) 0.74 0.913 BAB
Table 5.  Summary crude odds ratios (ORs) and 95% confidence intervals (95% CI) for recessive and 
dominant models for variants that were identified for meta-analysis with credibility factors in paediatric 
UC. Venice criteria grade for the three criteria. The first grade is for the amount of evidence assessed according 
to statistical power (A, ≥ 80%; B, 50–79%; C, < 50%); the second grade is for the extent of replication assessed 
according to heterogeneity (I2 value: A, < 25%; B, 25–50%; C, > 50%); the third grade is for protection from 
bias assessed according to small study effect (complete assessment of bias is difficult; no variants were graded 
as “A”; “B” was assigned for studies which no small study effect was detected; otherwise, “C” was assigned). 
Bayesian False Discovery Probability (BFDP) value were calculated at prior probability of 0.05. BFDP level of 
noteworthiness is 0.2.
Gene/ Variant
Cases vs. 
controls 
(number of 
samples)
ADDITIVE MODEL 1: var/wt VS. wt/wt ADDITIVE MODEL 2: var/var VS. wt/wt
N Effect size Heterogeneity Credibility N Effect size Heterogeneity Credibility
OR (95% 
CI) P value
I^2 
(95% CI) Power BFDP1
Venice 
criteria 
grade
OR (95% 
CI) P value
I^2 
(95% CI) Power BFDP1
Venice 
criteria 
grade
NOD2/rs2066844 590 vs. 1512 (6) 6
1.73  
(1.25, 2.36) 8.80E-04 34 (0, 91) 0.88 0.215 ABB 4
1.02 (0.21, 
5.00) 0.980 0 (0, 79) 0.05 0.959 CAB
NOD2/rs2066845 591 vs. 1515 (6) 6
1.11  
(0.68, 1.84) 0.600 0 (0, 87) 0.09 0.976 CAB 2
3.06 (0.16, 
57.43) 0.455 0 (0, 0) 0.28 0.951 CAB
NOD2/rs2066847 593 vs. 1502 (6) 6
1.79  
(1.13, 2.84) 0.010 0 (0, 0) 0.74 0.785 BAB n/a n/a n/a n/a n/a n/a n/a
IL23R/ 
rs11209026
393 vs. 
1321(3) 3
0.56  
(0.37, 0.85) 0.007 0 (0, 83) 0.84 0.677 AAB n/a n/a n/a n/a n/a n/a n/a
IBD5/rs1050152 353 vs. 1056 (4) 4
1.12  
(0.84, 1.50) 0.430 0 (0, 76) 0.12 0.983 CAB 4
1.52 (1.06, 
2.17) 0.022 0 (0, 90) 0.66 0.848 BAB
IBD5/rs26313667 353 vs. 1044 (4) 4
1.22  
(0.89, 1.67) 0.209 0 (0, 91) 0.25 0.971 CAB 4
1.49 (1.04, 
2.13) 0.031 0 (0, 87) 0.61 0.876 BAB
DLG5/rs1248696 289 vs. 800 (3) 3
0.86  
(0.58, 1.27) 0.450 0 (0, 62) 0.14 0.978 CAB 3
0.72 (0.16, 
3.24) 0.664 0 (0, 97) 0.06 0.958 CAB
TNF-α/rs1800629 235 vs. 844 (3) 3
1.65  
(1.10, 2.47) 0.015 61 (0, 99) 0.83 0.802 ACB 3
3.34 (1.09, 
10.22) 0.035 0 (0, 98) 0.80 0.889 AAB
Table 6.  Summary crude odds ratios (ORs) and 95% confidence intervals (95% CI) for two additive models for 
variants that were identified for meta-analysis with credibility factors in paediatric UC. Venice criteria grade for 
the three criteria. The first grade is for the amount of evidence assessed according to statistical power (A, ≥ 80%;  
B, 50–79%; C, < 50%); the second grade is for the extent of replication assessed according to heterogeneity (I2 value: 
A, < 25%; B, 25–50%; C, > 50%); the third grade is for protection from bias assessed according to small study effect 
(complete assessment of bias is difficult; no variants were graded as “A”; “B” was assigned for studies which no small 
study effect was detected; otherwise, “C” was assigned). Bayesian False Discovery Probability (BFDP) value were 
calculated at prior probability of 0.05. BFDP level of noteworthiness is 0.2.
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credibility indicate more genetic and biological studies are needed; weakly genetic associations may be not worthy 
of further investigation unless strong mechanistic evidence has been demonstrated.
One of the potential obstacles to distinguish the genetic susceptibility of paediatric IBD from adult-onset 
disease is the difficulty of recruiting affected children in sufficient numbers to have adequate statistical power 
to detect and characterize association. GWAS have shown that odds ratios of genome wide significant genetic 
variants in IBD are small and thus sample sizes need to be very large to identify variants specific to paediatric 
IBD with moderate or small effect sizes7–9. Given the limited sample sizes in the meta-analyses of paediatric IBD, 
this field synopsis is likely to be subject to false negatives. To overcome this problem, international collaboration 
is required in the future study to enlarge the sample size and multiple controls per case would increase power.
For epigenetic studies, there is widespread concern about the gene-set analysis approach generally applied 
in genome-wide methylation assays, which is severely biased as a result of differences in the numbers of CpG 
sites associated with different classes of genes and gene promoters43. New analytical methods developed for epig-
enomic analysis are required to avoid bias. Epigenetic research in paediatric IBD is just in its infancy; the heter-
ogeneity among studies precludes a robust interpretation of results. Further well-designed studies are needed to 
clarify the role of epigenetic mechanisms in paediatric IBD pathogenesis.
In summary, our study supports the highly credible associations of 9 genetic variants with paediatric IBD, 
of which 4 variants had not been previously identified in paediatric GWAS. SNPs identified for paediatric IBD 
have been found also to be implicated in adult IBD and there is no evidence that genetic effects are of greater 
magnitude in children. Differential DNA methylation in NOD2 and TNF-α, dysregulated expression in let-7 and 
miR-124 were putatively associated with paediatric IBD, and worthy of further investigation. There is the pos-
sibility that genetic variations outside the investigated genes and unexplored genetic-environment interactions 
may modulate the early age of disease onset. Further progress identifying genetic susceptibility loci and epigenetic 
changes specific to paediatric IBD will require international collaboration to increase statistical power, population 
diversity, and for epigenetic changes, harmonization of protocols for investigation and an open-ness to share data.
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